Last reviewed · How we verify
NNC0215-0384
At a glance
| Generic name | NNC0215-0384 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis (PHASE1)
- A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0215-0384 CI brief — competitive landscape report
- NNC0215-0384 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI